Therefore, disrupting the PD-1/PD-L1 complex at the cancer cell-T cell interface restores lymphocyte activity and has become an attractive target for pharmaceutical companies resulting in the development of potent monoclonal antibody-based therapies that have demonstrated remarkable therapeutic successes. This evidence concerns the gene PDCD1 and cancer.